SurVaxM vaccine for lung cancer prevention in high-risk smokers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational vaccine (SurVaxM) to see if it can help prevent lung cancer in people at high risk, such as long-term smokers. The vaccine aims to train your immune system to fight off lung cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Have a significant smoking history (at least 20 pack-years).
- Have a high lung cancer risk score (above 1.34%) based on a standard screening tool.
- Be generally healthy enough for daily activities (ECOG performance status 0 or 1).
- Have adequate kidney and liver function (based on blood tests).
- If you can become pregnant or father a child, agree to use birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a vaccine called CIMAvax-EGF with a KRAS G12C inhibitor to treat advanced lung cancer with a specific genetic change. The goal is to see if adding this vaccine helps the targeted therapy work better or longer.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
This trial tests a vaccine made from a lung-cancer target (MUC1) to help your immune system recognize and fight the cancer. It is designed to measure immune response and safety, and it may help some people develop a stronger anti-cancer immune reaction.
This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Hear when a new Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.